Skip to main content
A person wearing a mask receives a shot in their arm

Global HIV Vaccine Enterprise Industry Partnership

The Global HIV Vaccine Enterprise Industry Partnership is establishing a forum to bring about the full contribution of the biomedical industry to address the complexities of HIV vaccine R&D. Its goal is to reignite the interest of the biomedical industry, funders and academics in the search for an HIV vaccine by regaining the pharmaceutical industry’s confidence in what is now a publicly led effort.

In a changing HIV prevention landscape, the Vaccine group can provide the foundation and environment for change and increase the chances of developing and rolling out a safe and globally effective HIV vaccine. The group will focus on:

  • Increasing the visibility of academic vaccine R&D to the biopharmaceutical industry
  • Bringing together businesses working in all areas of vaccine discovery, development, manufacturing and distribution
  • Providing a neutral space for interactions between industry and academia
  • Facilitating interactions with normative agencies and global implementers
  • Improving stakeholders' understanding of barriers to product development
  • Encouraging and facilitating sharing of information and expertise
  • Engaging with low-and middle-income countries to support forming international partnerships and facilitate product development and local testing in the interest of their citizens
  • Supporting exchange programmes between academia and industry
  • Supporting end-to-end good practice for product development

Interested in joining? Please contact [email protected].

Meet the Vaccine group members

Co-chairs

Carey Hwang
Carey Hwang

Carey Hwang

Vir Biotechnology, Inc
United States
View
Linda-Gail Bekker
Headshot of Linda-Gail Bekker

Linda-Gail Bekker

Desmond Tutu HIV Centre Institute of Infectious Disease and Molecular Medicine, UCT Faculty of Health Sciences
South Africa
View

Industry members

James F Rooney
James F Rooney

James F Rooney

Gilead Sciences
United States
View
Jan van Lunzen
Jan van Lunzen

Jan van Lunzen

ViiV Healthcare
United Kingdom
View
Bonnie Howell
Bonnie Howell

Bonnie Howell

Merck & Co., Inc
View
Hanneke Schuitemaker
Hanneke Schuitemaker

Hanneke Schuitemaker

Janssen Vaccines & Prevention B.V
View
Jim Tartaglia
Jim Tartaglia

Jim Tartaglia

Sanofi Vaccines
United States
View
Jeffrey Safrit
Jeffrey Safrit

Jeffrey Safrit

ImmunityBio
View
Shan Lu
Shan Lu

Shan Lu

University of Massachusetts Medical School
United States
View
Jo Kennelly
Jo Kennelly

Jo Kennelly

Malaika Vx Inc. & Global Health Systems
View

Non-industry members

Gabriella Scarlatti
Gabriella Scarlatti

Gabriella Scarlatti

San Raffaele Scientific Institute
Italy
View
Rogier Sanders
Rogier Sanders

Rogier Sanders

Netherlands
View
Sheena McCormack
Sheena McCormack

Sheena McCormack

MRC Clinical Trials Unit at UCL
United Kingdom
View
Dan Barouch
Dan Barouch

Dan Barouch

View
Larry Corey
Larry Corey

Larry Corey

Fred Hutchinson Cancer Research Center
United States
View
Gerald Voss
Gerald Voss

Gerald Voss

TuBerculosis Vaccine Initiative (TBVI)
Belgium
View
Maureen Luba
Maureen Luba

Maureen Luba

Malawi
View
Susan Buchbinder
Susan Buchbinder

Susan Buchbinder

Department of Epidemiology & Biostatistics, School of Medicine, University of California, San Francisco
United States
View
Maeva Villard
Maeva Villard

Maeva Villard

International AIDS Society
View
Nelli Barrière
Nelli Barrière

Nelli Barrière

International AIDS Society
View
Carole Beilleau
Carole Beilleau

Carole Beilleau

Director, Development and Partnerships
International AIDS Society
View
Tuuli Reissaar
Tuuli Reissaar

Tuuli Reissaar

International AIDS Society
View
Julieta Firmat
Julieta Firmat

Julieta Firmat

International AIDS Society
View